Keyword: Kenneth Frazier

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.

There are a lot of intermediate players in today’s pharma supply chain. But expect that to change, Merck CEO Ken Frazier said Wednesday.

A policy change by the board of Merck & Co. will allow Ken Frazier to remain CEO after he turns 65 next year.

A closer look at the Merck's new pricing plan reveals it really isn’t changing all that much, analysts say.

HHS Secretary Alex Azar pledged shame, anger and discount-minded Medicare drug plans to fight high prices.

Merck's Keytruda ginned up $1.46 billion in the first quarter, but analysts grilled CEO Ken Frazier about his plans to deliver new backup.

Merck’s Kenneth Frazier is breaking his silence about his decision last August to resign from the president's manufacturing council.

Does industry still fear the threat of pricing reform from the Trump Administration?

As the drug industry took heat in 2017 for "getting away with murder," among other criticisms, its lobbyists were busy behind the scenes.

Payer discounts are likely to grow even if midterm elections revive attacks on the industry—and investors should be worried about that, analysts say.